The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2

被引:4
|
作者
Hu, Yuan [1 ]
Liu, Lili [1 ]
Zhang, Shenghua [1 ]
Su, Shaoyu [1 ]
Liang, Xiao [1 ]
机构
[1] Sichuan Univ, West China Univ Hosp 2, Key Lab Birth Defects & Related Dis Women & Childr, Dev & Related Dis Women & Children Key Lab Sichuan, Chengdu 610041, Peoples R China
来源
ACS OMEGA | 2024年 / 9卷 / 05期
关键词
NEUTRALIZING ANTIBODY-RESPONSES; DRUG-DELIVERY-SYSTEMS; DELTA INULIN; NANOPARTICLE VACCINE; ANTIVIRAL ACTIVITY; POTENT VACCINE; DOUBLE-BLIND; IN-VITRO; T-CELL; ADJUVANT;
D O I
10.1021/acsomega.3c08326
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The coronavirus disease-19 (COVID-19) pandemic has had a significant impact on human life worldwide since 2019. Specific vaccines and antiviral agents are the most effective means of preventing and treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Additionally, antiviral protective equipment and early diagnosis also contribute to controlling the spread of COVID-19. The utilization of biomaterials in medicine and pharmaceuticals is crucial to ensure the positive impact of vaccines, antiviral agents, and protective equipment. In this review, we discuss the application of various types of biomaterials, including polymers, lipid nanoparticles, inorganic biomaterials, protein- or peptide-associated biomaterials, self-assembled biomaterials, and other biomaterials, for the vaccine, treatment, and prevention of COVID-19. Finally, we provide a perspective on future opportunities and challenges for developing biomaterials to combat other viral outbreaks and diseases.
引用
收藏
页码:5175 / 5192
页数:18
相关论文
共 50 条
  • [41] SARS-CoV-2 vaccine as a potential trigger for narcolepsy
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2022, 18 (10): : 2519 - 2519
  • [42] A systematic review of SARS-CoV-2 vaccine candidates
    Dong, Yetian
    Dai, Tong
    Wei, Yujun
    Zhang, Long
    Zheng, Min
    Zhou, Fangfang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [43] Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
    Duarte, Nathan
    Yanes-Lane, Mercedes
    Arora, Rahul K.
    Bobrovitz, Niklas
    Liu, Michael
    Bego, Mariana G.
    Yan, Tingting
    Cao, Christian
    Gurry, Celine
    Hankins, Catherine A.
    Cheng, Matthew Pellan
    Gingras, Anne-Claude
    Mazer, Bruce D.
    Papenburg, Jesse
    Langlois, Marc-Andre
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (02):
  • [44] Immune imprinting and SARS-CoV-2 vaccine design
    Wheatley, Adam K.
    Fox, Annette
    Tan, Hyon-Xhi
    Juno, Jennifer A.
    Davenport, Miles P.
    Subbarao, Kanta
    Kent, Stephen J.
    TRENDS IN IMMUNOLOGY, 2021, 42 (11) : 956 - 959
  • [45] Eosinophilic Pneumonia Associated to SARS-CoV-2 Vaccine
    Costa e Silva, Margarida
    Sa Marques, Marta
    Joao, David
    Campainha, Sergio
    ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 : 51 - 52
  • [46] SARS-CoV-2 vaccine candidates in rapid development
    Li, Lifeng
    Guo, Pengbo
    Zhang, Xiaoman
    Yu, Zhidan
    Zhang, Wancun
    Sun, Huiqing
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 644 - 653
  • [47] Development of SARS-CoV-2 Vaccine: Challenges and Prospects
    Mahboob, Tooba
    Ismail, Amni Adilah
    Shah, Muhammad Raza
    Rahmatullah, Mohammed
    Paul, Alok K.
    Pereira, Maria de Lourdes
    Wiart, Christophe
    Wilairatana, Polrat
    Rajagopal, Mogana
    Dolma, Karma G.
    Nissapatorn, Veeranoot
    DISEASES, 2023, 11 (02)
  • [48] A SARS-CoV-2 mRNA Vaccine - Preliminary Report
    Jackson, Lisa A.
    Roberts, Paul C.
    Graham, Barney S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (12): : 1190 - 1192
  • [49] Approaches and Challenges in SARS-CoV-2 Vaccine Development
    Dagotto, Gabriel
    Yu, Jingyou
    Barouch, Dan H.
    CELL HOST & MICROBE, 2020, 28 (03) : 364 - 370
  • [50] The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2
    Morris, Kevin V.
    MOLECULAR THERAPY, 2020, 28 (07) : 1548 - 1549